In vitro and in vivo studies showed good biodistribution and tumour to background ratios for 99mTc, 123I, 124I and 76Br labelled human recombinant anti-ED-B fibronectin antibody fragments, but clinical studies were generally not attempted [30,32,33,114]. Here, FN1 is linked to neoplasm.